Story
SK Biopharmaceuticals Stock Soars on $795 Million Epilepsy Drug Deal

SK Biopharmaceuticals (326030.KS) shares jumped as much as 10.5% on Wednesday following the announcement of a significant global licensing deal to acquire an epilepsy treatment pipeline from Biohaven Bioscience Ireland. The agreement bolsters the company's portfolio in a core therapeutic area, signaling a substantial investment in future growth.
Deal Details
The deal gives SK Biopharmaceuticals worldwide rights to Biohaven's epilepsy drug candidate, Opakalim, along with a suite of related Kv7 activator compounds and the underlying discovery platform. The total potential value of the acquisition is up to $795 million.
SK Biopharmaceuticals will make an upfront payment of $400 million, structured as $350 million at closing and an additional $50 million one year later. The company described the transaction as one of its most significant pipeline investments to date, aimed at strengthening its position in the neurology market.
AdMarket Context and Performance
The market's positive reaction comes amid already strong commercial momentum for SK Biopharmaceuticals. The acquisition of an early-stage asset complements the company's proven commercial success with its existing epilepsy drug, Cenobamate.
According to a recent note from Heungkuk Securities, which reiterated a Buy rating on the stock, Cenobamate saw a 24% year-on-year increase in prescriptions in July. The company also reported strong second-quarter results, with consolidated revenue reaching 247.4 billion KRW, a 40.3% increase from the previous year. The broader KOSPI index was also up approximately 0.9% during Wednesday's trading session.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.